Brief: GreenPeptide says initiation of a phase II clinical trial of the cancer peptide vaccine GRN-1201 in US
27/01/2017 07:40
Jan 27 (Reuters) - GreenPeptide Co Ltd 4594.T :
* Says the initiation of a phase II clinical trial of the
cancer peptide vaccine GRN-1201 with the concomitant use of an
immune checkpoint antibody against non-small cell lung cancer in
the United States
Source text in Japanese: https://goo.gl/ZWztFT
Further company coverage: 4594.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 62674724;
Reuters Messaging: Cheng.Li@thomsonreuters.com@reuters.net))